title: Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride.
abstract: Studies of subjective wellbeing (SW) in schizophrenia have missed to define and to assess rate and predictors of SW response (SW-res) and SW remission (SW-rem).
  
  
  METHODS
  A total of 727 patients with schizophrenia and severely impaired SW at entry (Subjective Wellbeing under Neuroleptics Scale, short version, SWN-K, total score < or =60) were treated with amisulpride over 12 weeks. SW-res was defined as SWN total score increase of at least 20% and by at least 10 points and SW-rem as total score of > or =80 points.
  
  
  RESULTS
  Seventy percent fulfilled the SW-res criterion at week 4. At week 4 and week 12 (endpoint), the SW response criterion distinguished between patients with or without later SW remission and overall symptomatic and functional response. While 39% fulfilled the SW-rem criterion at endpoint, only 9.1% without early SW-res were in SW-rem at follow-up. Regression analyses indicated that SW-res was mainly predicted by greater severity of positive symptoms at baseline and SW-rem by lower severity of negative symptoms and better social functioning, and particularly by early SW-res.
  
  
  CONCLUSIONS
  Patients with a risk of SW non-remission need to be identified early with subsequent treatment adaptation according to recommendations for incomplete remission and treatment resistance in schizophrenia.
authors.affiliation: Psychosis Early Detection and Intervention Centre (PEDIC), Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy of the University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. lambert@uke.uni-hamburg.de
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.forename: D
authors.initials: D
authors.lastname: Naber
authors.forename: F X
authors.initials: FX
authors.lastname: Eich
authors.forename: M
authors.initials: M
authors.lastname: Schacht
authors.forename: M
authors.initials: M
authors.lastname: Linden
authors.forename: B G
authors.initials: BG
authors.lastname: Schimmelmann
mesh_terms: D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology*; D012074:Remission Induction; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride